ArticleVirology2014
BST2/CD317 counteracts human coronavirus 229E productive infection by tethering virions at the cell surface.
Article in Virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 45 citations in OpenAlex.
- BST-2 inhibits SARS-CoV-2 egress at intracellular membranes and is neutralized by ORF7a.Scientific reports · 2026Article
- Exosome Tethering Requires Tetherin Homodimerisation.Biology of the cell · 2025Article
- Review
- PGAP3 regulates human bronchial epithelial cell mRNAs present in asthma and respiratory virus reference data sets.medRxiv : the preprint server for health sciences · 2024Article
- Mutations accumulated in the Spike of SARS-CoV-2 Omicron allow for more efficient counteraction of the restriction factor BST2/Tetherin.PLoS pathogens · 2024Article
- Tetherin antagonism by SARS-CoV-2 ORF3a and spike protein enhances virus release.EMBO reports · 2023Article
- Development of animal models for emerging infectious diseases by breaking the barrier of species susceptibility to human pathogens.Emerging microbes & infections · 2023Article
- Article
- Article
- Persistence of a Frameshifting Deletion in SARS-CoV-2 ORF7a for the Duration of a Major Outbreak.Viruses · 2023Article
- The envelope proteins from SARS-CoV-2 and SARS-CoV potently reduce the infectivity of human immunodeficiency virus type 1 (HIV-1).Retrovirology · 2022Article
- Review
- Interferon induction, evasion, and paradoxical roles during SARS-CoV-2 infection.Immunological reviews · 2022Review
- Interferon Control of Human Coronavirus Infection and Viral Evasion: Mechanistic Insights and Implications for Antiviral Drug and Vaccine Development.Journal of molecular biology · 2022Review
- CD317-Positive Immune Stromal Cells in Human "Mesenchymal Stem Cell" Populations.Frontiers in immunology · 2022Article
- Choosing a cellular model to study SARS-CoV-2.Frontiers in cellular and infection microbiology · 2022Review
- Functional landscape of SARS-CoV-2 cellular restriction.Molecular cell · 2021Article
- Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis.Clinical microbiology reviews · 2021Review
- Imaging of SARS-CoV-2 infected Vero E6 cells by helium ion microscopy.Beilstein journal of nanotechnology · 2021Article
- Determining How Coronaviruses Overcome the Interferon and Innate Immune Response.Methods in molecular biology (Clifton, N.J.) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone marrow stromal antigen 2 (BST2), an interferon-inducible antiviral factor, has been shown to block the release of various enveloped viruses from cells. It has also been identified as an innate immune system component. Most enveloped viruses subject to BST2 restriction bud at the plasma membrane. Here we report our findings that (a) the production of human coronavirus 229E (HCoV-229E) progeny viruses, whose budding occurs at the ER-Golgi intermediate compartment (ERGIC), markedly decreases in the presence of BST2; and (b) BST2 knockdown expression results in enhanced HCoV-229E virion production. Electron microscopy analyses indicate that HCoV-229E virions are tethered to cell surfaces or intracellular membranes by BST2. Our results suggest that BST2 exerts a broad blocking effect against enveloped virus release, regardless of whether budding occurs at the plasma membrane or intracellular compartments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.